Skip to main content
. 2018 Nov 14;12(2):269–281. doi: 10.1016/j.tranon.2018.09.015

Figure 6.

Figure 6

Bortezomib treatment inhibited patient-derived xenografts in NSG mice.

Relative tumor growth of PDX models treated with vehicle (control) (A) 14-GS076, n = 5; (B) 14GS-084, n = 4; (C) 15GS-023, n = 5, or bortezomib (0.3 mg/kg) (A) 14-GS076, n = 5; (B) 14GS-084, n = 6; (C) 15GS-023, n = 7. Mice were treated with either bortezomib (0.3 mg/kg body weight, in DMSO/PBS) or DMSO/PBS. The mice were monitored and weighed three times a week. Data shown represent the mean ± SEM (*P < .05; **P < .01).